Industry, Sector and Symbol:
- Sector: Medical
- Industry: Biotechnology
- Sub-Industry: N/A
- Symbol: NASDAQ:MRTX
- CUSIP: N/A
- Web: www.mirati.com
- Market Cap: $81.05 million
- Outstanding Shares: 24,939,000
- 50 Day Moving Avg: $4.03
- 200 Day Moving Avg: $5.10
- 52 Week Range: $3.10 - $19.25
Sales & Book Value:
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -1.50
- P/E Growth: 0.00
- Annual Revenue: N/A
- Price / Sales: N/A
- Book Value: $3.97 per share
- Price / Book: 0.82
- EBIDTA: ($77,080,000.00)
- Return on Equity: -89.06%
- Return on Assets: -78.73%
- Current Ratio: 5.53%
- Quick Ratio: 5.53%
- Average Volume: 137,211 shs.
- Beta: 1.15
- Short Ratio: 7.02
Frequently Asked Questions for Mirati Therapeutics (NASDAQ:MRTX)
What is Mirati Therapeutics' stock symbol?
Mirati Therapeutics trades on the NASDAQ under the ticker symbol "MRTX."
How were Mirati Therapeutics' earnings last quarter?
Mirati Therapeutics, Inc. (NASDAQ:MRTX) released its quarterly earnings results on Thursday, March, 9th. The company reported ($0.99) EPS for the quarter, missing analysts' consensus estimates of ($0.97) by $0.02. View Mirati Therapeutics' Earnings History.
Where is Mirati Therapeutics' stock going? Where will Mirati Therapeutics' stock price be in 2017?
8 analysts have issued 12-month price objectives for Mirati Therapeutics' shares. Their predictions range from $5.50 to $27.00. On average, they anticipate Mirati Therapeutics' stock price to reach $13.07 in the next year. View Analyst Ratings for Mirati Therapeutics.
What are analysts saying about Mirati Therapeutics stock?
Here are some recent quotes from research analysts about Mirati Therapeutics stock:
- 1. According to Zacks Investment Research, "Mirati Therapeutics, Inc. is a biopharmaceutical company. It engaged in the development of novel therapeutics for the treatment of cancer. Mirati Therapeutics, Inc., formerly known as MethylGene Inc., is based in Montreal, Canada. " (5/4/2017)
- 2. Jefferies Group LLC analysts commented, "MRTX reported clinical updates on lead programs, glesatinib and sitravatinib. ID’ing glesatinib’s optimal patient pop (MET amp) as well as better safety w/ lower discontinuation rate on new formulation could start to pay off as more pts enter ph.II, which could help enable them to show whether activity is differentiated. Sitravatinib data remains early." (1/9/2017)
Who are some of Mirati Therapeutics' key competitors?
Some companies that are related to Mirati Therapeutics include Trevena (TRVN), Foamix Pharmaceuticals Ltd (FOMX), Athersys (ATHX), MannKind (MNKD), Mediwound Ltd (MDWD), Vascular Biogenics Ltd (VBLT), Recro Pharma (REPH), Uniqure NV (QURE), Oncomed Pharmaceuticals (OMED), Evogene Ltd (EVGN), Fate Therapeutics (FATE), Conatus Pharmaceuticals (CNAT), Pluristem Therapeutics (PSTI), BioDelivery Sciences International (BDSI), Sorrento Therapeutics (SRNE), CymaBay Therapeutics (CBAY), 22nd Century Group (XXII) and VIVUS (VVUS).
Who owns Mirati Therapeutics stock?
Mirati Therapeutics' stock is owned by many different of institutional and retail investors. Top institutional investors include Aviva Holdings Ltd. (11.55%), Broadfin Capital LLC (8.38%), Boxer Capital LLC (4.16%), Vanguard Group Inc. (2.75%), Sabby Management LLC (1.00%) and Renaissance Technologies LLC (0.66%). Company insiders that own Mirati Therapeutics stock include Boxer Capital, Llc, Bros Advisors Lp Baker, Charles M Baum, Ltd Braslyn and Mark J Gergen. View Institutional Ownership Trends for Mirati Therapeutics.
Who sold Mirati Therapeutics stock? Who is selling Mirati Therapeutics stock?
Mirati Therapeutics' stock was sold by a variety of institutional investors in the last quarter, including JPMorgan Chase & Co., Morgan Stanley, TIAA CREF Investment Management LLC, UBS Group AG and Alliancebernstein L.P.. View Insider Buying and Selling for Mirati Therapeutics.
Who bought Mirati Therapeutics stock? Who is buying Mirati Therapeutics stock?
Mirati Therapeutics' stock was bought by a variety of institutional investors in the last quarter, including Broadfin Capital LLC, Aviva Holdings Ltd., Boxer Capital LLC, Renaissance Technologies LLC, Vanguard Group Inc., Sabby Management LLC, Royce & Associates LP and Dimensional Fund Advisors LP. Company insiders that have bought Mirati Therapeutics stock in the last two years include Boxer Capital, Llc, Bros Advisors Lp Baker, Charles M Baum and Ltd Braslyn. View Insider Buying and Selling for Mirati Therapeutics.
How do I buy Mirati Therapeutics stock?
Shares of Mirati Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Mirati Therapeutics' stock price today?
MarketBeat Community Rating for Mirati Therapeutics (NASDAQ MRTX)MarketBeat's community ratings are surveys of what our community members think about Mirati Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
One share of Mirati Therapeutics stock can currently be purchased for approximately $3.25.
Earnings History for Mirati Therapeutics (NASDAQ:MRTX)Earnings History by Quarter for Mirati Therapeutics (NASDAQ:MRTX)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
Earnings Estimates for Mirati Therapeutics (NASDAQ:MRTX)
2017 EPS Consensus Estimate: ($3.62)
(Data provided by Zacks Investment Research)
|Quarter||Number of Estimates||Low Estimate||High Estimate||Average Estimate|
Dividend History for Mirati Therapeutics (NASDAQ:MRTX)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Mirati Therapeutics (NASDAQ:MRTX)
Insider Ownership Percentage: 4.80%Insider Trades by Quarter for Mirati Therapeutics (NASDAQ:MRTX)
Institutional Ownership Percentage: 50.41%
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|1/26/2017||Ltd. Braslyn||Major Shareholder||Buy||48,169||$5.45||$262,521.05|| |
|1/25/2017||Ltd. Braslyn||Major Shareholder||Buy||30,600||$5.42||$165,852.00|| |
|1/24/2017||Ltd. Braslyn||Major Shareholder||Buy||27,682||$5.32||$147,268.24|| |
|1/23/2017||Ltd. Braslyn||Major Shareholder||Buy||19,251||$5.27||$101,452.77|| |
|1/20/2017||Ltd. Braslyn||Major Shareholder||Buy||61,158||$5.46||$333,922.68|| |
|1/17/2017||Ltd. Braslyn||Major Shareholder||Buy||119,887||$5.50||$659,378.50|| |
|1/6/2017||Boxer Capital, Llc||Major Shareholder||Buy||286,163||$5.60||$1,602,512.80|| |
|6/14/2016||Charles M Baum||CEO||Buy||20,000||$7.05||$141,000.00|| |
|6/9/2016||Bros. Advisors Lp Baker||Major Shareholder||Sell||999,358||$9.41||$9,403,958.78|| |
|6/7/2016||Ltd. Braslyn||Major Shareholder||Buy||376,902||$9.96||$3,753,943.92|| |
|5/6/2016||Ltd. Braslyn||Major Shareholder||Buy||65,782||$18.21||$1,197,890.22|| |
|3/28/2016||Ltd. Braslyn||Major Shareholder||Buy||20,848||$19.36||$403,617.28|| |
|3/18/2016||Ltd. Braslyn||Major Shareholder||Buy||1,166||$19.34||$22,550.44|| |
|1/15/2016||Mark J. Gergen||COO||Sell||10,000||$25.92||$259,200.00|| |
|9/16/2015||Bros. Advisors Lp Baker||Major Shareholder||Buy||150,000||$45.00||$6,750,000.00|| |
|5/26/2015||Jamie Christensen||SVP||Sell||4,750||$28.07||$133,332.50|| |
|3/5/2015||Jamie Christensen||SVP||Sell||6,000||$25.41||$152,460.00|| |
|2/19/2015||Jamie Christensen||SVP||Sell||4,750||$22.84||$108,490.00|| |
|2/3/2015||Orbimed Advisors Llc||Major Shareholder||Buy||100,000||$20.00||$2,000,000.00|| |
|1/29/2015||Bros. Advisors Lp Baker||Major Shareholder||Buy||425,000||$20.00||$8,500,000.00|| |
|7/1/2014||Orbimed Advisors Llc||Major Shareholder||Sell||107,332||$21.66||$2,324,811.12|| |
|11/26/2013||Charles M Baum||CEO||Buy||5,000||$16.96||$84,800.00|| |
|10/29/2013||Orbimed Advisors Llc||Major Shareholder||Buy||125,000||$17.50||$2,187,500.00|| |
|10/24/2013||Tang Capital Partners Lp||Major Shareholder||Buy||57,143||$17.50||$1,000,002.50|| |
|9/20/2013||Tang Capital Partners Lp||Major Shareholder||Sell||36,898||$16.34||$602,913.32|| |
Headline Trends for Mirati Therapeutics (NASDAQ:MRTX)
Latest Headlines for Mirati Therapeutics (NASDAQ:MRTX)
|Mirati Therapeutics, Inc. (MRTX) Given Average Recommendation of "Hold" by Brokerages|
www.americanbankingnews.com - May 19 at 9:01 AM
|Q2 2017 Earnings Estimate for Mirati Therapeutics, Inc. Issued By Jefferies Group (MRTX)|
www.americanbankingnews.com - May 10 at 8:14 AM
|Zacks: Brokerages Expect Mirati Therapeutics, Inc. (MRTX) to Announce -$0.77 EPS|
www.americanbankingnews.com - May 9 at 8:10 AM
|Zacks Investment Research Lowers Mirati Therapeutics, Inc. (MRTX) to Hold|
www.americanbankingnews.com - May 7 at 8:55 PM
|Mirati reports 1Q loss|
marketbeat.com - May 4 at 6:57 PM
|Mirati Therapeutics Reports First Quarter 2017 Financial Results|
finance.yahoo.com - May 4 at 6:45 PM
|Positive Media Coverage Extremely Likely to Affect Mirati Therapeutics (MRTX) Stock Price|
www.americanbankingnews.com - May 2 at 8:52 AM
|Mirati Therapeutics (MRTX) Given Daily News Impact Rating of 0.37|
www.americanbankingnews.com - April 28 at 6:18 PM
|Mirati Therapeutics (MRTX) Getting Somewhat Favorable Media Coverage, AlphaOne Reports|
www.americanbankingnews.com - April 25 at 9:22 PM
|Mirati Therapeutics (MRTX) Earning Somewhat Negative News Coverage, Study Finds|
www.americanbankingnews.com - April 22 at 8:06 AM
|Mirati Therapeutics (MRTX) Earning Positive News Coverage, Study Finds|
www.americanbankingnews.com - April 18 at 2:00 PM
|Mirati Therapeutics, Inc. (MRTX) Given Hold Rating at Jefferies Group LLC|
www.americanbankingnews.com - April 18 at 8:59 AM
|Positive Press Coverage Extremely Likely to Impact Mirati Therapeutics (MRTX) Share Price|
www.americanbankingnews.com - April 13 at 8:59 AM
|Mirati Therapeutics' (MRTX) Hold Rating Reaffirmed at Jefferies Group LLC|
www.americanbankingnews.com - April 12 at 3:14 PM
|Mirati Therapeutics, Inc. (MRTX) Sees Significant Increase in Short Interest|
www.americanbankingnews.com - April 8 at 9:30 AM
|Mirati Therapeutics, Inc. (MRTX) Receives Consensus Recommendation of "Hold" from Analysts|
www.americanbankingnews.com - March 28 at 12:16 PM
|MIRATI THERAPEUTICS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and Ex|
biz.yahoo.com - March 27 at 6:10 PM
|MIRATI THERAPEUTICS, INC. Financials|
finance.yahoo.com - March 15 at 6:51 PM
|Mirati Therapeutics Reports Financial Results And Provides Business Update For The Fourth Quarter And Full Year 2016|
finance.yahoo.com - March 9 at 6:27 PM
|MIRATI THERAPEUTICS, INC. Files SEC form 10-K, Annual Report|
biz.yahoo.com - March 9 at 6:27 PM
|Mirati Therapeutics To Present At Leerink Partners 6th Annual Global Healthcare Conference|
finance.yahoo.com - February 13 at 7:48 PM
|MIRATI THERAPEUTICS, INC. Files SEC form 8-K, Change in Directors or Principal Officers|
biz.yahoo.com - February 8 at 7:32 PM
|Mirati Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriter's Option to Purchase Additional Shares|
finance.yahoo.com - January 11 at 7:15 PM
|Mirati Launches $65M Public Stock Offering (MRTX)|
www.investopedia.com - January 9 at 7:21 PM
|Mirati Therapeutics Sets $65M Public Offering|
www.investopedia.com - January 9 at 7:21 PM
|MRTX Prices Offering At $5.60/Share|
www.nasdaq.com - January 9 at 4:26 AM
|7:31 am Mirati Therapeutics prices an underwritten public offering of 4,350,176 shares of its common stock at a price to the public of $5.60/share|
us.rd.yahoo.com - January 6 at 7:21 PM
|MIRATI THERAPEUTICS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits|
biz.yahoo.com - January 6 at 7:21 PM
|Mirati Therapeutics (MRTX) Offers Data from on Glesatinib and Sitravatinib Clinical Trials - StreetInsider.com|
www.streetinsider.com - January 6 at 1:06 AM
|Mirati Therapeutics (MRTX) Plans Offering of Common Stock|
www.streetinsider.com - January 5 at 8:05 PM
|4:02 pm Mirati Therapeutics announces data from 2 ongoing clinical programs including the Phase 1b & Phase 2 trials of glesatinib; co intends to offer & sell shares of its common stock|
finance.yahoo.com - January 5 at 8:05 PM
|MIRATI THERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Other Events|
biz.yahoo.com - January 5 at 8:05 PM
|How Mirati Therapeutics (MRTX) Stock Stands Out in a Strong Industry|
finance.yahoo.com - December 9 at 6:41 PM
Mirati Therapeutics (MRTX) Chart for Monday, May, 29, 2017